How should a 2.9 × 2.5 × 2.4 cm adrenal mass, previously 2.6 × 2.7 × 2.7 cm three months ago and identified as a lipid‑rich adenoma on MRI, be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Lipid-Rich Adrenal Adenoma <4 cm with Minimal Growth

This lipid-rich adenoma measuring 2.9 cm with minimal growth (3 mm over 3 months) does not require further follow-up imaging or functional testing. 1

Rationale for No Further Follow-Up

The 2023 CUA/AUA guidelines provide clear direction for this clinical scenario:

  • Benign non-functional adenomas <4 cm confirmed as lipid-rich on MRI do not require any additional imaging or functional testing. 1

  • The tumor growth of approximately 3 mm over 3 months falls well below the threshold for concern. Lesions growing <3 mm/year do not require further imaging follow-up or functional testing. 1

  • Even if this growth rate continued, it would only represent 12 mm/year, which still warrants consideration for surgery only when growth exceeds 5 mm/year after repeating functional work-up. 1

Initial Functional Testing Required (If Not Already Done)

Before discontinuing surveillance, ensure the following screening has been completed:

  • All patients with adrenal incidentalomas must be screened for autonomous cortisol secretion using 1 mg dexamethasone suppression testing. 1

  • Screening for pheochromocytoma is NOT needed in patients with unequivocal lipid-rich adenomas (HU <10 on CT or confirmed on MRI) who have no signs or symptoms of adrenergic excess. 1

  • If hypertension or hypokalemia is present, screen for primary aldosteronism with aldosterone-to-renin ratio. 1

Key Supporting Evidence

Prospective data confirms the safety of this approach: A 5-year follow-up study of lipid-rich adrenal incidentalomas <40 mm with <10 HU demonstrated mean tumor growth of only 1±2 mm, with no patients developing clinically relevant tumor growth or new subclinical hypercortisolism. 2 The largest tumor growth in that cohort was 8 mm over 5 years, which proved to be a benign cortical adenoma on surgical pathology. 2

Critical Pitfalls to Avoid

  • Do not continue surveillance imaging simply because the mass is present. The guidelines explicitly state no further follow-up is needed for confirmed benign adenomas <4 cm. 1, 3

  • Ensure the MRI truly confirms lipid-rich adenoma. Homogeneous signal intensity drop on chemical shift MRI is diagnostic of lipid-rich adenoma, while heterogeneous signal drop can occur in pheochromocytoma, adrenocortical carcinoma, and some metastases. 1

  • The 4 cm threshold is firm. If this lesion were ≥4 cm, repeat imaging in 6-12 months would be indicated even if radiologically benign. 1

When to Reconsider Imaging

Repeat imaging would only be warranted if:

  • The patient develops new symptoms suggesting hormone excess (Cushing's features, hypertension with hypokalemia, or adrenergic symptoms). 1

  • There is clinical suspicion for interval growth based on symptoms or physical examination changes. 1

  • Initial functional testing reveals mild autonomous cortisol secretion requiring annual clinical screening for metabolic comorbidities. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Adrenal tumors: how to establish malignancy ?

Journal of endocrinological investigation, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.